High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study
We report promising efficacy and good tolerability of Bruton tyrosine kinase (BTK) inhibitor ibrutinib in treatment of newly diagnosed PCNSL. Additionally, we explored the contribution of ctDNA profiling to predictive potential in this prospective study. The consistency of ctDNA clearance from CSF/plasma was associated with more sustained treatment response and survival.
Authors
- Zhiming Li (ORCID: https://orcid.org/0000-0001-9730-9917)
- Haoqing Chen (ORCID: https://orcid.org/0000-0002-7803-1654)
- Xiaoyu Hong (ORCID: https://orcid.org/0009-0003-0483-7094)
- Bing Bai (ORCID: https://orcid.org/0000-0003-3708-7640)
- Hui Zhou (ORCID: https://orcid.org/0000-0001-9909-5051)
- Linbo Cai (ORCID: https://orcid.org/0000-0001-8108-467X)
- Changguo Shan (ORCID: https://orcid.org/0000-0002-5211-4670)
- Xiaoxiao Wang (ORCID: https://orcid.org/0000-0003-0568-263X)
- Huiqiang Huang (ORCID: https://orcid.org/0000-0002-9090-1907)
- Yan Gao (ORCID: https://orcid.org/0000-0002-1268-2999)
- He Huang
- Cheng Huang (ORCID: https://orcid.org/0000-0003-1358-6293)
- Mingyao Lai (ORCID: https://orcid.org/0009-0009-4564-1139)
- Liqin Ping
Institutions
- Central South University (CN)
- Sun Yat-sen University (CN)
- Qujing Normal University (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
- Hunan Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangdong 999 Brain Hospital (CN)
Publication Details
- Journal
- Blood Cancer Discovery
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1158/2643-3230.bcd-24-0156
- Citations
- 6
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 8.34
Funders
- National Natural Science Foundation of China